动脉样硬化中的差异性蛋白质糖表达改变了血小板粘附和激活
Amelia Drysdale1, Maria Blanco-Lopez1, Stephen J White2
1Department of Life Sciences, Manchester Metropolitan University, Manchester M1 5GD, UK.
International journal of molecular sciences
|January 23, 2024
概括
动脉样硬化斑块中的蛋白质糖抑制了血小板血栓的形成,提供了潜在的新疗法. 不同类型的斑块对抗血小板药物的反应不同,影响治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 血栓形成研究研究
- 细胞外矩阵生物学 细胞外矩阵生物学
背景情况:
- 蛋白质甘氨酸如大甘氨酸,氨酸,氨酸和氨酸在动脉样硬化斑块表型中具有差异表达.
- 斑块破坏暴露了细胞外矩阵 (ECM) 蛋白质,启动了血小板粘附和血栓形成.
研究的目的:
- 研究不同斑块组成对血小板功能和血栓形成的影响.
- 在剪切应力下评估蛋白质糖和斑块复合物的血小板粘附,激活和血栓形成.
主要方法:
- 在不同的剪切条件下评估了血小板粘附,激活和血栓形成.
- 使用单个蛋白质糖和ECM复合物,代表破裂和侵蚀的斑块表型.
- 评估了可溶性蛋白质糖对血小板对原蛋白的反应的影响.
主要成果:
- 所有测试的蛋白质甘氨酸均调解了血小板粘附,但没有激活,粘附度低于原蛋白.
- 与单独的原蛋白相比,斑块复合材料上的血栓形成显著减少,这表明蛋白质甘油可以负面调节血小板原蛋白反应.
- 溶解的biglycan和decorin显著减少了I型原体上的血栓形成.
- 侵蚀复合物形成血栓是对阿司匹林敏感的,而破裂复合物是阿司匹林密集的.
结论:
- 在斑块破裂和侵蚀表型之间存在不同的血小板反应和抗血小板功效.
- 蛋白质糖抑制了血栓形成,这表明一种新的斑块特异性方法来限制动脉血栓形成.
- 这些发现对基于斑块特征的当前抗血小板治疗方案有影响.
相关概念视频
Formation of the Platelet Plug
6.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Inflammation
53.4K
Overview
53.4K
Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701


